ArticleNature medicine2024

Author Correction: Duvelisib plus romidepsin in relapsed/refractory T cell lymphomas: a phase 1b/2a trial.

Steven M Horwitz et al.PubMed ↗Publisher ↗

No numbers read from the abstract.